

Supplementary Table S1. STROBE Statement—Checklist of items that should be included in reports of cohort studies.²³

	Item		Met or
	No	Recommendation	Unmet
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	Met
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Met
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Met
Objectives	3	State specific objectives, including any prespecified hypotheses	Met
Methods			
Study design	4	Present key elements of study design early in the paper	Met
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Met
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	Met
		(b) For matched studies, give matching criteria and number of exposed and unexposed	N/A

Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Met
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Met
Bias	9	Describe any efforts to address potential sources of bias	Met
Study size	10	Explain how the study size was arrived at	Met
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Met
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Met
		(b) Describe any methods used to examine subgroups and interactions	Met
		(c) Explain how missing data were addressed	Met
		(d) If applicable, explain how loss to follow-up was addressed	N/A
		(e) Describe any sensitivity analyses	Met
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Met
		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	Met

Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Met
		(b) Indicate number of participants with missing data for each variable of interest	Met
		(c) Summarise follow-up time (eg, average and total amount)	Met
Outcome data	15*	Report numbers of outcome events or summary measures over time	Met
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Met
		(b) Report category boundaries when continuous variables were categorized	Met
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Met
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Met
Discussion			
Key results	18	Summarise key results with reference to study objectives	Met
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Met
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Met

Generalisability	21	Discuss the generalisability (external validity) of the study results	Met
------------------	----	---	-----

Other information

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Met
---------	----	---	-----

Supplementary Table S2. Competing risk comparisons for key variables.

Variable	Censored (non TB & non death) (n=8196)	TB (n=287)	death (n=10506)	p-value
Gender				
Female n (%)	3683 (44.9)	101 (35.2)	5173 (49.2)	
Male n (%)	4513 (55.1)	186 (64.8)	5333 (50.8)	< 0.001
Age_CKD5 mean (sd)	59.8 (13.7)	63.1 (11.9)	71.4 (12.9)	< 0.001
Age group and CKD5				
Below 50 years old n (%)	1581 (19.3)	25 (8.7)	3173 (30.2)	< 0.001
50-59 years old n (%)	1957 (23.9)	68 (23.7)	1337 (12.7)	
60-69 years old n (%)	2496 (30.5)	86 (30)	2495 (23.7)	
70-79 years old n (%)	1581 (19.3)	67 (23.3)	2940 (28)	
80 years old and above n (%)	451 (5.5)	25 (8.7)	3173 (30.2)	
Ethnicity				
Chinese n (%)	5246 (64)	183 (63.8)	7327 (69.7)	< 0.001
Indian n (%)	620 (7.6)	14 (4.9)	773 (7.4)	
Malay n (%)	2156 (26.3)	85 (29.6)	2228 (21.2)	
Others n (%)	174 (2.1)	5 (1.7)	178 (1.7)	
Smoking				
Never smoked n (%)	5348 (65.3)	66 (23)	6689 (63.7)	
Ever smoked n (%)	2576 (31.4)	98 (34.1)	3522 (33.5)	< 0.001
N/A n (%)	272 (3.3)	123 (42.9)	295 (2.8)	
ESRD_EGFR mean(sd)	12 (6.2)	11.6 (3.1)	12.1 (2.8)	0.088
Mean creatinine at 1 st dialysis (sd)	8.9 (3.6)	9.1 (3.5)	7.5 (3)	< 0.001
Modality type	912 (11.1)	46 (16)	4896 (46.6)	< 0.001
No dialysis n (%)	597 (7.3)	20 (7)	402 (3.8)	

PD only n (%)	5719 (69.8)	185 (64.5)	4394 (41.8)	
HD only n (%)	968 (11.8)	36 (12.5)	814 (7.7)	
PD + HD n (%)				
Transplant				
No n (%)	7667 (93.5)	284 (99)	10481 (99.8)	
Yes n (%)	529 (6.5)	3 (1)	25 (0.2)	< 0.001
Diabetes mellitus				
Non-diabetic n (%)	2704 (33)	79 (27.5)	2313 (22)	< 0.001
Diabetic n (%)	5491 (67)	208 (72.5)	8193 (78)	
N/A n (%)	1 (0)	0 (0)	0 (0)	
History of malignancy				
No n (%)	7388 (90.1)	266 (92.7)	9013 (85.8)	
Yes n (%)	807 (9.8)	21 (7.3)	1493 (14.2)	< 0.001
N/A n (%)	1 (0)	0 (0)	0 (0)	